Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.73 USD | +0.41% | -0.91% | -32.21% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.21% | 936M | |
+26.65% | 49.18B | |
+0.66% | 42.11B | |
+50.35% | 40.37B | |
-5.26% | 28.85B | |
+12.47% | 26.09B | |
-21.91% | 18.71B | |
+8.41% | 13.26B | |
+31.14% | 12.32B | |
-0.20% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating